首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1881980

苯達莫司汀市場報告：趨勢、預測和競爭分析（至2031年）

Bendamustine Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年12月02日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

由於醫院、癌症診所和居家醫療市場的需求，全球苯達莫司汀市場預計將保持強勁成長。預計2025年至2031年，全球苯達莫司汀市場將以5.4%的複合年成長率成長。推動該市場成長的主要因素包括血液系統癌症發病率的上升、對有效化療的需求不斷成長以及苯達莫司汀核准用於多種適應症。

Lucintel 預測，根據診斷標準，慢性淋巴性白血病在預測期內將呈現最高的成長率。
從最終用途來看，癌症診所預計將呈現最高的成長率。
從區域來看，預計亞太地區在預測期內將達到最高的成長率。

苯達莫司汀市場的新趨勢

苯達莫司汀市場正經歷著一場意義深遠的變革時期，其驅動力在於不斷湧現的新趨勢，這些趨勢旨在提升苯達莫司汀的療效、安全性和患者便利性。這些趨勢正推動治療方案從「一刀切」式轉向高度精準的標靶治療，以更好地解決癌症的潛在機制。隨著對個人化治療和先進技術的日益重視，市場也在不斷發展演變。

非專利競爭加劇：這一趨勢指的是苯達莫司汀專利到期後，市場上學名藥藥數量不斷增加。其目的是提供更具成本效益的治療方案。這加劇了市場競爭，並有助於降低整體治療成本。患者用藥便利性的提高，尤其是在新興市場，迫使生產者專注於產品差異化和改善治療效果。
新型聯合治療：苯達莫司汀正積極與新型標靶治療（如Rituximab）和免疫療法合併應用，以期提高療效並實現綜合治療。這些聯合治療可同時針對多個癌症通路，產生協同效應，從而提高患者的緩解率並無惡化生存期。
新型製劑的研發：此一趨勢的重點在於開發新型苯達莫司汀製劑，例如即用型注射液，這將提高病患和醫師的用藥便利性。這些新型製劑將縮短配製時間，降低給藥錯誤風險，使臨床給藥過程更有效率且安全，這對於風險複雜的藥物而言至關重要。
拓展治療適應症：這一趨勢探討了苯達莫司汀在骨髓惡性腫瘤以外的新適應症中的應用潛力。臨床研究已檢驗對多發性骨髓瘤和某些固態腫瘤等疾病有效。這將顯著拓寬其市場應用範圍，為生產商開闢新的機會和收入來源。
以患者為中心的照護：這一新興趨勢著重於將苯達莫司汀治療與以患者為中心的護理措施（例如居家照護和數位健康平台）相結合，以提高患者的生活品質和治療依從性。這些措施為患者提供便利和支持，減少了患者頻繁就診的需要，並確保更好的治療效果。

這些趨勢共同重塑了市場格局，使苯達莫司汀從傳統的化療藥物轉變為高度精密、以患者為中心、數據驅動的解決方案。其關注點正轉向綜合辦法，優先考慮患者安全、便利性和與現代醫療環境的無縫銜接，以實現更好、更永續的患者療效。

本達莫司汀市場的最新發展

苯達莫司汀市場正受到近期一系列發展的影響，這些發展對產品供應、臨床實踐和市場結構都產生了重大影響。這些進步是由技術創新、不斷變化的醫療保健需求以及對高效安全藥品生產日益重視共同推動的。這些發展使得苯達莫司汀更有效、更容易取得且使用方便。

藥物製劑的進展：近期一項重大進展是推出了新型製劑，例如即用型液體注射劑，作為傳統凍乾粉劑的替代品，不僅使用更加便捷，而且配製時間更短。這對於繁忙的診所和醫院來說是一項重大改進，它降低了配製過程中出錯的風險，並確保為患者提供更標準化的產品。
治療適應症拓展：苯達莫司汀的應用範圍正在不斷擴大，涵蓋多發性骨髓瘤和某些固態腫瘤等新的治療領域。這拓寬了該藥物的市場覆蓋率，使其能夠治療更多患者，並為生產商開闢新的機會和收入來源。
學名藥和生物相似藥的興起：近期，學名藥的供應量不斷增加，加劇了市場競爭，降低了成本，使更多患者，尤其是在新興經濟體的患者中，能夠更便捷、更經濟地獲得苯達莫司汀治療。這促使生產商更加重視產品差異化。
新型聯合治療的臨床原理：近期進展包括發表長期臨床數據，支持苯達莫司汀與其他標靶治療聯合使用，這增強了臨床醫生的信心，並證明它可以成為傳統治療方法的安全有效替代方案，從而提高了臨床醫生採用新治療通訊協定的意願。
策略併購：市場呈現大型製藥企業收購或與腫瘤專科公司建立合作關係的趨勢。這種整合使市場領導能夠快速採用新技術並擴展產品系列。這加快了創新產品的上市速度，提高了其服務更廣泛地域的能力，並確保了穩定可靠的供應鏈。

這些發展正在影響整個市場，推動癌症治療轉向以患者為中心、技術主導的方法轉變，這不僅提高了藥物質量，還提高了流程效率，增強了安全性，並融入了更廣泛的製藥生態系統。

The future of the global bendamustine market looks promising with opportunities in the hospital, oncology clinic, and homecare setting markets. The global bendamustine market is expected to grow with a CAGR of 5.4% from 2025 to 2031. The major drivers for this market are the increasing incidence of hematologic cancers, the rising demand for effective chemotherapy treatments, and the growing approval of bendamustine for multiple indications.

Lucintel forecasts that, within the indication category, chronic lymphocytic leukemia is expected to witness the highest growth over the forecast period.
Within the end use category, oncology clinic is expected to witness the highest growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Bendamustine Market

The bendamustine market is undergoing a significant transformation with emerging trends focused on improving its efficacy, safety, and patient convenience. These trends are moving beyond a one-size-fits-all approach to create highly sophisticated, targeted therapies that better address the underlying mechanisms of cancer. The market is evolving with a greater emphasis on personalization and advanced technology.

Rise of Generic Competition: This trend involves the increasing availability of generic versions of bendamustine, following patent expirations. The goal is to provide cost-effective treatment options. The impact is a significant increase in market competition and a reduction in the overall cost of treatment. This enhances patient access, particularly in emerging markets, and forces manufacturers to focus on product differentiation and improving patient outcomes.
New Combination Therapies: There is a growing focus on using bendamustine in combination with new targeted therapies and immunotherapies, such as rituximab. The impact is enhanced efficacy and a more comprehensive approach to treatment. By targeting multiple cancer pathways simultaneously, these combinations offer a synergistic effect, leading to higher response rates and longer progression-free survival in patients.
Development of Novel Formulations: This trend is centered on creating new bendamustine formulations, such as ready-to-use liquid injections. The impact is enhanced patient and physician convenience. These new formulations reduce the preparation time and the risk of dosing errors, making the administration process more efficient and safer in a clinical setting, which is crucial for a drug with a complex risk profile.
Expanded Therapeutic Indications: This trend involves exploring the use of bendamustine for new indications beyond its primary use in hematological malignancies. Clinical research is investigating its efficacy in conditions like multiple myeloma and certain solid tumors. The impact is a significant expansion of the market's applications, opening up new opportunities and revenue streams for manufacturers.
Patient-Centric Care: This emerging trend focuses on integrating bendamustine treatment with patient-centric care initiatives, such as home-based care and digital health platforms. The impact is improved patient quality of life and treatment adherence. These initiatives provide convenience and support to patients, reducing the need for frequent hospital visits and ensuring better overall outcomes.

These trends are collectively reshaping the market by transforming bendamustine from a traditional chemotherapy drug into a highly sophisticated, patient-centric, and data-driven solution. The focus is shifting towards a holistic approach that prioritizes patient safety, convenience, and seamless integration with the modern healthcare environment to achieve better and more durable patient outcomes.

Recent Developments in the Bendamustine Market

The bendamustine market is being impacted by a series of recent developments that are significantly influencing product offerings, clinical practices, and market structure. These advancements are driven by a combination of technological innovation, evolving healthcare needs, and a greater emphasis on efficient and safe pharmaceutical production. These developments are making bendamustine more effective, accessible, and user-friendly.

Advancements in Drug Formulation: A key recent development is the introduction of new formulations, such as ready-to-use liquid injections, to replace the traditional lyophilized powder. The impact is enhanced convenience and reduced preparation time. This is a significant improvement for busy clinics and hospitals, reducing the risk of reconstitution errors and ensuring a more standardized product for patients.
Expansion of Therapeutic Indications: The market has seen developments in the use of bendamustine for new therapeutic applications, such as for the treatment of multiple myeloma and certain solid tumors. The impact is an expansion of the drug's market reach. This allows for a wider patient population to be treated with bendamustine, opening up new opportunities and revenue streams for manufacturers.
Rise of Generic and Biosimilar Versions: Recent developments include the increasing availability of generic and biosimilar versions of bendamustine. The impact is increased market competition and reduced costs. This makes bendamustine treatment more accessible and affordable for a larger number of patients, particularly in emerging economies, and encourages manufacturers to focus on product differentiation.
Clinical Evidence for New Combinations: Recent developments include the publication of long-term clinical data supporting the use of bendamustine in combination with other targeted therapies. The impact is increased confidence among clinicians. This evidence demonstrates that these combinations can be a safe and effective alternative to traditional therapies, leading to a greater willingness among clinicians to adopt these new treatment protocols.
Strategic Mergers and Acquisitions: The market is witnessing a trend of major pharmaceutical companies acquiring or partnering with specialized oncology firms. This consolidation allows market leaders to quickly integrate new technologies and expand their product portfolios. The impact is a faster path to market for innovative products and a greater ability to serve a wider geographic area, ensuring a more stable and reliable supply chain.

These developments are collectively impacting the market by fostering a shift towards a more patient-centric and technology-driven approach to cancer treatment. They are not only improving the quality of the drug but are also making the process more efficient, safer, and more integrated into the broader pharmaceutical ecosystem.

Strategic Growth Opportunities in the Bendamustine Market

The bendamustine market is presenting significant strategic growth opportunities across key applications, driven by a growing focus on hematological cancers, specialized therapies, and the modernization of healthcare infrastructure. By targeting these specific applications, companies can expand their market presence and cater to the unique needs of different user segments, from high-volume hospitals to specialized clinics.

Non-Hodgkin's Lymphoma: This is the largest and most significant growth opportunity. As a growing number of patients are diagnosed with NHL, there is a consistent demand for bendamustine-based treatments, particularly in combination with rituximab. The impact is a high-volume, high-value market where a focus on product innovation and a robust supply chain can lead to significant market share gains.
Chronic Lymphocytic Leukemia: This application presents a major growth opportunity. Bendamustine is a standard of care for many patients with CLL, particularly in the relapsed or refractory setting. The impact is a high-volume market where a focus on cost-effective, high-purity products can be a key differentiator, and is less reliant on traditional hospital settings.
Multiple Myeloma: This application presents a significant growth opportunity. Bendamustine is being increasingly explored and used for treating multiple myeloma, particularly in patients who have relapsed. The impact is a high-value, niche market segment that requires a strong focus on safety, efficacy, and adherence to stringent quality and safety standards, as it is used in combination with other drugs.
Myeloid Sarcoma: The market for bendamustine in the treatment of myeloid sarcoma represents a major growth opportunity. The focus is on providing a versatile drug for a wide range of difficult-to-treat conditions. The impact is a long-term growth strategy that requires a strong focus on building relationships with clinicians and a deep understanding of complex treatment needs.
Emerging Economies: The markets in China, India, and other emerging economies represent a major growth opportunity. The focus is on providing cost-effective and reliable bendamustine to meet the rising demand for oncology care. The impact is a long-term growth strategy that requires a strong focus on local manufacturing, accessible pricing, and building a local distribution network.

These opportunities are impacting the market by encouraging diversification and specialization. Companies are now able to create products and services that cater to the unique needs of different applications, leading to a more segmented and competitive market that is better equipped to serve the distinct needs of a wide range of patients and healthcare providers.

Bendamustine Market Driver and Challenges

The bendamustine market is influenced by a combination of key drivers and challenges, which include various technological, economic, and regulatory factors. Understanding these forces is essential for market players to develop effective strategies and maintain a competitive edge. The market's trajectory is shaped by factors that both foster growth and create significant obstacles.

The factors responsible for driving the bendamustine market include:

1. Increasing Prevalence of Hematological Cancers: The rising global incidence of hematological cancers, such as non-Hodgkin's lymphoma and CLL, is the primary driver. This creates a large and expanding patient pool requiring effective long-term treatment. This trend provides a consistent and robust demand for bendamustine, which is the backbone of these medications.

2. Advancements in Combination Therapies: The development of new and improved combination therapies, such as the use of bendamustine with rituximab, is a major driver. These innovations offer better outcomes, reduced side effects, and enhanced patient satisfaction. This is pushing for greater adoption of new, advanced products that are more effective than traditional monotherapies.

3. Growing Geriatric Population: The global aging population is a major driver of the market. As people live longer, the incidence of age-related diseases that require bendamustine, such as CLL and NHL, increases. This demographic trend creates a large patient segment that is a primary user of bendamustine-based medications.

4. Favorable Regulatory Approvals: The approval of new bendamustine formulations and combination therapies by regulatory bodies like the FDA and EMA is a key driver. This regulatory support provides a strong signal of trust and safety to healthcare providers. This is encouraging greater adoption and improved patient access to the drug.

5. Shift to Outpatient and Home-Based Care: The shift towards outpatient and home-based cancer treatment is a major driver. New bendamustine formulations, such as ready-to-use liquid injections, are well-suited for these settings, as they simplify administration and reduce the need for frequent hospital visits. This is making treatment more convenient for patients.

Challenges in the bendamustine market are:

1. High Cost of Treatment: The high cost of branded bendamustine and new combination therapies is a significant challenge. This can be a barrier to widespread adoption, particularly in healthcare systems with budget constraints or in developing regions where reimbursement is not readily available, limiting market growth in those areas.

2. Severe Side Effects: The potential for severe, life-threatening side effects, such as myelosuppression and infections, is a significant challenge. This requires careful patient selection and monitoring, which can be a barrier to its use. This risk limits the use of the drug in certain patient populations and requires careful patient selection and monitoring.

3. Competition from Novel Therapies: The market faces strong competition from new targeted therapies and immunotherapies, such as CAR-T cell therapy. These alternatives may be preferred by clinicians in certain cases, and their development requires continuous innovation from bendamustine manufacturers to remain relevant in a competitive oncology landscape.

The overall impact of these drivers and challenges is a market that is dynamic and highly competitive. While powerful drivers like a growing patient population and technological innovation are propelling growth, significant challenges related to cost, side effects, and competition are creating a more deliberate and cautious adoption cycle. Successfully addressing these challenges will be key for future market leaders.

List of Bendamustine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bendamustine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bendamustine companies profiled in this report include-

Fresenius Kabi
Mylan
Merck
Eisai
Aspen Pharmacare
Sun Pharma
Hikma Pharmaceuticals
Teva Pharmaceutical Industries
GSK
Roche

Bendamustine Market by Segment

The study includes a forecast for the global bendamustine market by indication, formulation, distribution channel, end use, and region.

Bendamustine Market by Indication [Value from 2019 to 2031]:

Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Multiple Myeloma
Others

Bendamustine Market by Formulation [Value from 2019 to 2031]:

Oral
Injectable

Bendamustine Market by Distribution Channel [Value from 2019 to 2031]:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Bendamustine Market by End Use [Value from 2019 to 2031]:

Hospitals
Oncology Clinics
Homecare Settings

Country Wise Outlook for the Bendamustine Market

Recent developments in the bendamustine market are driven by an increasing need for more effective and less toxic treatments for hematological cancers. Bendamustine's unique mechanism of action and its proven efficacy have solidified its position. The market is also being reshaped by a greater emphasis on new combination therapies, improved drug formulations, and the rising availability of generic versions to enhance patient access.

United States: The U.S. market is a global leader, driven by significant R&D investments and the early adoption of innovative drugs. Recent developments include FDA approvals for new bendamustine-based combination therapies and a growing emphasis on high-purity, ready-to-use liquid formulations. The market is also seeing increased investment in patient-centric care to improve treatment adherence and outcomes.
China: The Chinese market is a dominant force, leveraging a strong manufacturing base and a growing patient population. Recent developments are centered on advancing local clinical trials and regulatory approvals for new-generation drugs. There is a growing emphasis on a shift from traditional chemotherapy to more targeted, combination-based therapies to improve treatment efficacy and reduce side effects, which aligns with modern oncology practices.
Germany: Germany's market is characterized by a strong emphasis on evidence-based medicine and high-quality healthcare. Key developments include the growing adoption of new drug classes, although some may face reimbursement restrictions. The market is also seeing an increase in patient awareness campaigns and specialized cancer centers to improve diagnosis and provide targeted treatment plans, which is crucial for a drug with a complex risk profile.
India: The Indian market is witnessing significant growth, driven by a large patient pool and improving healthcare infrastructure. A key development is the rising demand for cost-effective bendamustine, with a focus on local manufacturing and generic versions to meet the needs of a large patient population. The market is also seeing a shift towards a more professionalized diagnosis and treatment in major urban hospitals.
Japan: The Japanese market is distinguished by its high adoption of sophisticated medical technologies and a rapidly aging population. Recent developments include the use of advanced formulations, such as lyophilized powder, to ensure the stability and safety of bendamustine. The market is also seeing a strong demand for products with proven long-term clinical data, reflecting a national preference for safety and efficacy in cancer treatment.

Features of the Global Bendamustine Market

Market Size Estimates: Bendamustine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Bendamustine market size by various segments, such as by indication, formulation, distribution channel, end use, and region in terms of value ($B).
Regional Analysis: Bendamustine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different indications, formulations, distribution channels, end uses, and regions for the bendamustine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bendamustine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the bendamustine market by indication (chronic lymphocytic leukemia, non-hodgkin's lymphoma, multiple myeloma, and others), formulation (oral and injectable), distribution channel (hospital pharmacies, retail pharmacies, and e-commerce), end use (hospitals, oncology clinics, and homecare settings), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Bendamustine Market by Indication

4.1 Overview
4.2 Attractiveness Analysis by Indication
4.3 Chronic Lymphocytic Leukemia: Trends and Forecast (2019-2031)
4.4 Non-Hodgkin's Lymphoma: Trends and Forecast (2019-2031)
4.5 Multiple Myeloma: Trends and Forecast (2019-2031)
4.6 Others: Trends and Forecast (2019-2031)

5. Global Bendamustine Market by Formulation

5.1 Overview
5.2 Attractiveness Analysis by Formulation
5.3 Oral: Trends and Forecast (2019-2031)
5.4 Injectable: Trends and Forecast (2019-2031)

6. Global Bendamustine Market by Distribution Channel

6.1 Overview
6.2 Attractiveness Analysis by Distribution Channel
6.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
6.4 Retail Pharmacies: Trends and Forecast (2019-2031)
6.5 E-commerce: Trends and Forecast (2019-2031)

7. Global Bendamustine Market by End Use

7.1 Overview
7.2 Attractiveness Analysis by End Use
7.3 Hospitals: Trends and Forecast (2019-2031)
7.4 Oncology Clinics: Trends and Forecast (2019-2031)
7.5 Homecare Settings: Trends and Forecast (2019-2031)

8. Regional Analysis

8.1 Overview
8.2 Global Bendamustine Market by Region

9. North American Bendamustine Market

9.1 Overview
9.2 North American Bendamustine Market by Indication
9.3 North American Bendamustine Market by End Use
9.4 United States Bendamustine Market
9.5 Mexican Bendamustine Market
9.6 Canadian Bendamustine Market

10. European Bendamustine Market

10.1 Overview
10.2 European Bendamustine Market by Indication
10.3 European Bendamustine Market by End Use
10.4 German Bendamustine Market
10.5 French Bendamustine Market
10.6 Spanish Bendamustine Market
10.7 Italian Bendamustine Market
10.8 United Kingdom Bendamustine Market

11. APAC Bendamustine Market

11.1 Overview
11.2 APAC Bendamustine Market by Indication
11.3 APAC Bendamustine Market by End Use
11.4 Japanese Bendamustine Market
11.5 Indian Bendamustine Market
11.6 Chinese Bendamustine Market
11.7 South Korean Bendamustine Market
11.8 Indonesian Bendamustine Market

12. ROW Bendamustine Market

12.1 Overview
12.2 ROW Bendamustine Market by Indication
12.3 ROW Bendamustine Market by End Use
12.4 Middle Eastern Bendamustine Market
12.5 South American Bendamustine Market
12.6 African Bendamustine Market

13. Competitor Analysis

13.1 Product Portfolio Analysis
13.2 Operational Integration
13.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

14.1 Value Chain Analysis
14.2 Growth Opportunity Analysis
- 14.2.1 Growth Opportunities by Indication
- 14.2.2 Growth Opportunities by Formulation
- 14.2.3 Growth Opportunities by Distribution Channel
- 14.2.4 Growth Opportunities by End Use
14.3 Emerging Trends in the Global Bendamustine Market
14.4 Strategic Analysis
- 14.4.1 New Product Development
- 14.4.2 Certification and Licensing
- 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

15.1 Competitive Analysis
15.2 Fresenius Kabi
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.3 Mylan
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.4 Merck
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.5 Eisai
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.6 Aspen Pharmacare
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.7 Sun Pharma
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.8 Hikma Pharmaceuticals
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.9 Teva Pharmaceutical Industries
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.10 GSK
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.11 Roche
- Company Overview
- Bendamustine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

16. Appendix

16.1 List of Figures
16.2 List of Tables
16.3 Research Methodology
16.4 Disclaimer
16.5 Copyright
16.6 Abbreviations and Technical Units
16.7 About Us
16.8 Contact Us

簡介目錄圖表

List of Figures

Figure 1.1: Trends and Forecast for the Global Bendamustine Market
Figure 2.1: Usage of Bendamustine Market
Figure 2.2: Classification of the Global Bendamustine Market
Figure 2.3: Supply Chain of the Global Bendamustine Market
Figure 3.1: Driver and Challenges of the Bendamustine Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Bendamustine Market by Indication in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Bendamustine Market ($B) by Indication
Figure 4.3: Forecast for the Global Bendamustine Market ($B) by Indication
Figure 4.4: Trends and Forecast for Chronic Lymphocytic Leukemia in the Global Bendamustine Market (2019-2031)
Figure 4.5: Trends and Forecast for Non-Hodgkin's Lymphoma in the Global Bendamustine Market (2019-2031)
Figure 4.6: Trends and Forecast for Multiple Myeloma in the Global Bendamustine Market (2019-2031)
Figure 4.7: Trends and Forecast for Others in the Global Bendamustine Market (2019-2031)
Figure 5.1: Global Bendamustine Market by Formulation in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Bendamustine Market ($B) by Formulation
Figure 5.3: Forecast for the Global Bendamustine Market ($B) by Formulation
Figure 5.4: Trends and Forecast for Oral in the Global Bendamustine Market (2019-2031)
Figure 5.5: Trends and Forecast for Injectable in the Global Bendamustine Market (2019-2031)
Figure 6.1: Global Bendamustine Market by Distribution Channel in 2019, 2024, and 2031
Figure 6.2: Trends of the Global Bendamustine Market ($B) by Distribution Channel
Figure 6.3: Forecast for the Global Bendamustine Market ($B) by Distribution Channel
Figure 6.4: Trends and Forecast for Hospital Pharmacies in the Global Bendamustine Market (2019-2031)
Figure 6.5: Trends and Forecast for Retail Pharmacies in the Global Bendamustine Market (2019-2031)
Figure 6.6: Trends and Forecast for E-commerce in the Global Bendamustine Market (2019-2031)
Figure 7.1: Global Bendamustine Market by End Use in 2019, 2024, and 2031
Figure 7.2: Trends of the Global Bendamustine Market ($B) by End Use
Figure 7.3: Forecast for the Global Bendamustine Market ($B) by End Use
Figure 7.4: Trends and Forecast for Hospitals in the Global Bendamustine Market (2019-2031)
Figure 7.5: Trends and Forecast for Oncology Clinics in the Global Bendamustine Market (2019-2031)
Figure 7.6: Trends and Forecast for Homecare Settings in the Global Bendamustine Market (2019-2031)
Figure 8.1: Trends of the Global Bendamustine Market ($B) by Region (2019-2024)
Figure 8.2: Forecast for the Global Bendamustine Market ($B) by Region (2025-2031)
Figure 9.1: North American Bendamustine Market by Indication in 2019, 2024, and 2031
Figure 9.2: Trends of the North American Bendamustine Market ($B) by Indication (2019-2024)
Figure 9.3: Forecast for the North American Bendamustine Market ($B) by Indication (2025-2031)
Figure 9.4: North American Bendamustine Market by End Use in 2019, 2024, and 2031
Figure 9.5: Trends of the North American Bendamustine Market ($B) by End Use (2019-2024)
Figure 9.6: Forecast for the North American Bendamustine Market ($B) by End Use (2025-2031)
Figure 9.7: Trends and Forecast for the United States Bendamustine Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Mexican Bendamustine Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Canadian Bendamustine Market ($B) (2019-2031)
Figure 10.1: European Bendamustine Market by Indication in 2019, 2024, and 2031
Figure 10.2: Trends of the European Bendamustine Market ($B) by Indication (2019-2024)
Figure 10.3: Forecast for the European Bendamustine Market ($B) by Indication (2025-2031)
Figure 10.4: European Bendamustine Market by End Use in 2019, 2024, and 2031
Figure 10.5: Trends of the European Bendamustine Market ($B) by End Use (2019-2024)
Figure 10.6: Forecast for the European Bendamustine Market ($B) by End Use (2025-2031)
Figure 10.7: Trends and Forecast for the German Bendamustine Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the French Bendamustine Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the Spanish Bendamustine Market ($B) (2019-2031)
Figure 10.10: Trends and Forecast for the Italian Bendamustine Market ($B) (2019-2031)
Figure 10.11: Trends and Forecast for the United Kingdom Bendamustine Market ($B) (2019-2031)
Figure 11.1: APAC Bendamustine Market by Indication in 2019, 2024, and 2031
Figure 11.2: Trends of the APAC Bendamustine Market ($B) by Indication (2019-2024)
Figure 11.3: Forecast for the APAC Bendamustine Market ($B) by Indication (2025-2031)
Figure 11.4: APAC Bendamustine Market by End Use in 2019, 2024, and 2031
Figure 11.5: Trends of the APAC Bendamustine Market ($B) by End Use (2019-2024)
Figure 11.6: Forecast for the APAC Bendamustine Market ($B) by End Use (2025-2031)
Figure 11.7: Trends and Forecast for the Japanese Bendamustine Market ($B) (2019-2031)
Figure 11.8: Trends and Forecast for the Indian Bendamustine Market ($B) (2019-2031)
Figure 11.9: Trends and Forecast for the Chinese Bendamustine Market ($B) (2019-2031)
Figure 11.10: Trends and Forecast for the South Korean Bendamustine Market ($B) (2019-2031)
Figure 11.11: Trends and Forecast for the Indonesian Bendamustine Market ($B) (2019-2031)
Figure 12.1: ROW Bendamustine Market by Indication in 2019, 2024, and 2031
Figure 12.2: Trends of the ROW Bendamustine Market ($B) by Indication (2019-2024)
Figure 12.3: Forecast for the ROW Bendamustine Market ($B) by Indication (2025-2031)
Figure 12.4: ROW Bendamustine Market by End Use in 2019, 2024, and 2031
Figure 12.5: Trends of the ROW Bendamustine Market ($B) by End Use (2019-2024)
Figure 12.6: Forecast for the ROW Bendamustine Market ($B) by End Use (2025-2031)
Figure 12.7: Trends and Forecast for the Middle Eastern Bendamustine Market ($B) (2019-2031)
Figure 12.8: Trends and Forecast for the South American Bendamustine Market ($B) (2019-2031)
Figure 12.9: Trends and Forecast for the African Bendamustine Market ($B) (2019-2031)
Figure 13.1: Porter's Five Forces Analysis of the Global Bendamustine Market
Figure 13.2: Market Share (%) of Top Players in the Global Bendamustine Market (2024)
Figure 14.1: Growth Opportunities for the Global Bendamustine Market by Indication
Figure 14.2: Growth Opportunities for the Global Bendamustine Market by Formulation
Figure 14.3: Growth Opportunities for the Global Bendamustine Market by Distribution Channel
Figure 14.4: Growth Opportunities for the Global Bendamustine Market by End Use
Figure 14.5: Growth Opportunities for the Global Bendamustine Market by Region
Figure 14.6: Emerging Trends in the Global Bendamustine Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Bendamustine Market by Indication, Formulation, Distribution Channel, and End Use
Table 1.2: Attractiveness Analysis for the Bendamustine Market by Region
Table 1.3: Global Bendamustine Market Parameters and Attributes
Table 3.1: Trends of the Global Bendamustine Market (2019-2024)
Table 3.2: Forecast for the Global Bendamustine Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Bendamustine Market by Indication
Table 4.2: Market Size and CAGR of Various Indication in the Global Bendamustine Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Indication in the Global Bendamustine Market (2025-2031)
Table 4.4: Trends of Chronic Lymphocytic Leukemia in the Global Bendamustine Market (2019-2024)
Table 4.5: Forecast for Chronic Lymphocytic Leukemia in the Global Bendamustine Market (2025-2031)
Table 4.6: Trends of Non-Hodgkin's Lymphoma in the Global Bendamustine Market (2019-2024)
Table 4.7: Forecast for Non-Hodgkin's Lymphoma in the Global Bendamustine Market (2025-2031)
Table 4.8: Trends of Multiple Myeloma in the Global Bendamustine Market (2019-2024)
Table 4.9: Forecast for Multiple Myeloma in the Global Bendamustine Market (2025-2031)
Table 4.10: Trends of Others in the Global Bendamustine Market (2019-2024)
Table 4.11: Forecast for Others in the Global Bendamustine Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Bendamustine Market by Formulation
Table 5.2: Market Size and CAGR of Various Formulation in the Global Bendamustine Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Formulation in the Global Bendamustine Market (2025-2031)
Table 5.4: Trends of Oral in the Global Bendamustine Market (2019-2024)
Table 5.5: Forecast for Oral in the Global Bendamustine Market (2025-2031)
Table 5.6: Trends of Injectable in the Global Bendamustine Market (2019-2024)
Table 5.7: Forecast for Injectable in the Global Bendamustine Market (2025-2031)
Table 6.1: Attractiveness Analysis for the Global Bendamustine Market by Distribution Channel
Table 6.2: Market Size and CAGR of Various Distribution Channel in the Global Bendamustine Market (2019-2024)
Table 6.3: Market Size and CAGR of Various Distribution Channel in the Global Bendamustine Market (2025-2031)
Table 6.4: Trends of Hospital Pharmacies in the Global Bendamustine Market (2019-2024)
Table 6.5: Forecast for Hospital Pharmacies in the Global Bendamustine Market (2025-2031)
Table 6.6: Trends of Retail Pharmacies in the Global Bendamustine Market (2019-2024)
Table 6.7: Forecast for Retail Pharmacies in the Global Bendamustine Market (2025-2031)
Table 6.8: Trends of E-commerce in the Global Bendamustine Market (2019-2024)
Table 6.9: Forecast for E-commerce in the Global Bendamustine Market (2025-2031)
Table 7.1: Attractiveness Analysis for the Global Bendamustine Market by End Use
Table 7.2: Market Size and CAGR of Various End Use in the Global Bendamustine Market (2019-2024)
Table 7.3: Market Size and CAGR of Various End Use in the Global Bendamustine Market (2025-2031)
Table 7.4: Trends of Hospitals in the Global Bendamustine Market (2019-2024)
Table 7.5: Forecast for Hospitals in the Global Bendamustine Market (2025-2031)
Table 7.6: Trends of Oncology Clinics in the Global Bendamustine Market (2019-2024)
Table 7.7: Forecast for Oncology Clinics in the Global Bendamustine Market (2025-2031)
Table 7.8: Trends of Homecare Settings in the Global Bendamustine Market (2019-2024)
Table 7.9: Forecast for Homecare Settings in the Global Bendamustine Market (2025-2031)
Table 8.1: Market Size and CAGR of Various Regions in the Global Bendamustine Market (2019-2024)
Table 8.2: Market Size and CAGR of Various Regions in the Global Bendamustine Market (2025-2031)
Table 9.1: Trends of the North American Bendamustine Market (2019-2024)
Table 9.2: Forecast for the North American Bendamustine Market (2025-2031)
Table 9.3: Market Size and CAGR of Various Indication in the North American Bendamustine Market (2019-2024)
Table 9.4: Market Size and CAGR of Various Indication in the North American Bendamustine Market (2025-2031)
Table 9.5: Market Size and CAGR of Various End Use in the North American Bendamustine Market (2019-2024)
Table 9.6: Market Size and CAGR of Various End Use in the North American Bendamustine Market (2025-2031)
Table 9.7: Trends and Forecast for the United States Bendamustine Market (2019-2031)
Table 9.8: Trends and Forecast for the Mexican Bendamustine Market (2019-2031)
Table 9.9: Trends and Forecast for the Canadian Bendamustine Market (2019-2031)
Table 10.1: Trends of the European Bendamustine Market (2019-2024)
Table 10.2: Forecast for the European Bendamustine Market (2025-2031)
Table 10.3: Market Size and CAGR of Various Indication in the European Bendamustine Market (2019-2024)
Table 10.4: Market Size and CAGR of Various Indication in the European Bendamustine Market (2025-2031)
Table 10.5: Market Size and CAGR of Various End Use in the European Bendamustine Market (2019-2024)
Table 10.6: Market Size and CAGR of Various End Use in the European Bendamustine Market (2025-2031)
Table 10.7: Trends and Forecast for the German Bendamustine Market (2019-2031)
Table 10.8: Trends and Forecast for the French Bendamustine Market (2019-2031)
Table 10.9: Trends and Forecast for the Spanish Bendamustine Market (2019-2031)
Table 10.10: Trends and Forecast for the Italian Bendamustine Market (2019-2031)
Table 10.11: Trends and Forecast for the United Kingdom Bendamustine Market (2019-2031)
Table 11.1: Trends of the APAC Bendamustine Market (2019-2024)
Table 11.2: Forecast for the APAC Bendamustine Market (2025-2031)
Table 11.3: Market Size and CAGR of Various Indication in the APAC Bendamustine Market (2019-2024)
Table 11.4: Market Size and CAGR of Various Indication in the APAC Bendamustine Market (2025-2031)
Table 11.5: Market Size and CAGR of Various End Use in the APAC Bendamustine Market (2019-2024)
Table 11.6: Market Size and CAGR of Various End Use in the APAC Bendamustine Market (2025-2031)
Table 11.7: Trends and Forecast for the Japanese Bendamustine Market (2019-2031)
Table 11.8: Trends and Forecast for the Indian Bendamustine Market (2019-2031)
Table 11.9: Trends and Forecast for the Chinese Bendamustine Market (2019-2031)
Table 11.10: Trends and Forecast for the South Korean Bendamustine Market (2019-2031)
Table 11.11: Trends and Forecast for the Indonesian Bendamustine Market (2019-2031)
Table 12.1: Trends of the ROW Bendamustine Market (2019-2024)
Table 12.2: Forecast for the ROW Bendamustine Market (2025-2031)
Table 12.3: Market Size and CAGR of Various Indication in the ROW Bendamustine Market (2019-2024)
Table 12.4: Market Size and CAGR of Various Indication in the ROW Bendamustine Market (2025-2031)
Table 12.5: Market Size and CAGR of Various End Use in the ROW Bendamustine Market (2019-2024)
Table 12.6: Market Size and CAGR of Various End Use in the ROW Bendamustine Market (2025-2031)
Table 12.7: Trends and Forecast for the Middle Eastern Bendamustine Market (2019-2031)
Table 12.8: Trends and Forecast for the South American Bendamustine Market (2019-2031)
Table 12.9: Trends and Forecast for the African Bendamustine Market (2019-2031)
Table 13.1: Product Mapping of Bendamustine Suppliers Based on Segments
Table 13.2: Operational Integration of Bendamustine Manufacturers
Table 13.3: Rankings of Suppliers Based on Bendamustine Revenue
Table 14.1: New Product Launches by Major Bendamustine Producers (2019-2024)
Table 14.2: Certification Acquired by Major Competitor in the Global Bendamustine Market

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

苯達莫司汀：全球市場佔有率和排名、總銷售額和需求預測（2025-2031 年）

FAQ

苯達莫司汀市場報告：趨勢、預測和競爭分析（至2031年）

Bendamustine Market Report: Trends, Forecast and Competitive Analysis to 2031

目錄

第1章執行摘要

第2章 市場概覽

第3章：市場趨勢與預測分析

4. 全球苯達莫司汀市場依適應症分類

5. 全球苯達莫司汀市場按劑型分類

6. 全球苯達莫司汀市場依通路分類

7. 全球苯達莫司汀市場依最終用途分類

第8章 區域分析

9. 北美苯達莫司汀市場

第10章歐洲苯達莫司汀市場

11.亞太地區苯達莫司汀市場

第12章 世界其他地區（ROW）本達莫斯汀市場

第13章 競爭分析

第14章：機會與策略分析

第15章 價值鏈中主要企業的概況

第16章附錄